Hemophilia is an inherited bleeding disorder wherein blood does not clot properly. Hemophilia can result into spontaneous bleeding within joints that can lead to chronic joint disease and pain, bleeding in the brain that can cause paralysis, and others. An individual suffering from this disorder either lacks or has low levels of proteins named clotting factor, mainly factor VIII and factor IX. There are three types of hemophilia – A, B, and C. Out of the three types, hemophilia A is the most common type of hemophilia.
Request for a FREE Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2012
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Global Hemophilia Treatment Market: Overview
The global hemophilia treatment market was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9% during the forecast period (2019-2027) owing to the rising incidence of hemophilia or bleeding disorders. According to Centers for Disease Control and Prevention (CDC) report, hemophilia affects 1 in 5,000 male births in the U.S. According to the World Federation of Hemophilia’s 2019 statistics of 115 countries, approximately 195,263 individuals were suffering from hemophilia and out of this, 157,517 individuals were suffering from hemophilia A. Thus, increasing prevalence of hemophilia across the globe is expected to drive the global hemophilia treatment market.
Increasing product launches, receiving approval from regulatory bodies, and increasing awareness programs on bleeding disorders are expected to boost the global hemophilia treatment market
Key players are adopting strategies such as product launches which is anticipated to drive the growth of the global hemophilia market during the forecast period. For instance, in April 2019, Roche Products India Pvt. Ltd, a wholly owned subsidiary of Roche Group, launched Emicizumab. This drug, branded as Hemlibra in India, is used for prophylactic treatment for controlling the frequency of bleeding in those patients suffering from hemophilia A, through Factor VIII inhibitors.
Moreover, major players are focused on receiving product approvals from the regulatory bodies in order to strengthen its product portfolio. For instance, in June 2019, Novo Nordisk, a global healthcare company, received marketing authorization in Europe for ‘Esperoct’ from the European Commission. Esperoct is the brand name for turoctocog alfa pegol, N8-GP. It is indicated for surgical procedures in adolescents and adults with hemophilia A. Furthermore, various agencies and organizations across the globe are taking initiatives to promote awareness about hemophilia treatment which is expected to drive the growth of the market during the forecast period. For instance, the Prevention of Complications of Hemophilia has established and coordinated a network of hemophilia treatment centers (HTCs) in collaboration with the National Hemophilia Foundation to promote the management, treatment, and prevention of complications associated with hemophilia and other hereditary bleeding disorders in the U.S. This collaboration mainly focuses on encouraging individuals to adopt healthy behaviors and participate in the HTC network and establish a reference library to diagnose rare bleeding disorders.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2012
Global hemophilia treatment market: Regional Analysis:
North America is expected to hold largest market share in the global hemophilia treatment market owing to the presence of key players in the region. Moreover, key players in the region are adopting strategies such as agreements and collaborations to strengthen their global presence and increase their product portfolio. For instance, in April 2014, Biogen, Inc., a bio-technology company, signed a license agreement with Amunix Operating Inc., a California-based biotechnology company, for research and development of novel, fully-recombinant Factor VIII products with improved therapeutic properties. As per this agreement, Biogen Inc. is focused on developing XTENylated Factor VIII products for the treatment of factor VIII deficiency.
Moreover, Asia Pacific is anticipated to exhibit a significant growth during the forecast period owing to rising favorable reimbursement policies for hemophilia treatment in countries such as China. For instance, according to the report published by the Chinese Ministry of Health in 2012, outpatient hemophilia treatment in China is covered by health insurance schemes in over 80% of the cities in China.
Global hemophilia treatment market: Competitive Landscape
Major players operating in the global hemophilia treatment market include F. Hoffmann-La Roche AG, Takeda Pharmaceutical Co., Ltd., Pfizer, Inc., Octapharma AG, Baxter International Inc., Biogen Inc., Swedish Orphan Biovitrum AB, Bayer AG, CSL Behring, Ferring B.V., Kedrion, Novo Nordisk A/S, and Sanofi S.A.
“Limited Period Offer”
Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2012
Main points in Hemophilia Treatment Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Hemophilia Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Hemophilia Treatment Industry Impact
Chapter 2 Hemophilia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Hemophilia Treatment (Volume and Value) by Type
2.3 Hemophilia Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Hemophilia Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Hemophilia Treatment Market Analysis
Chapter 6 East Asia Hemophilia Treatment Market Analysis
Chapter 7 Europe Hemophilia Treatment Market Analysis
Chapter 8 South Asia Hemophilia Treatment Market Analysis
Chapter 9 Southeast Asia Hemophilia Treatment Market Analysis
Chapter 10 Middle East Hemophilia Treatment Market Analysis
Chapter 11 Africa Hemophilia Treatment Market Analysis
Chapter 12 Oceania Hemophilia Treatment Market Analysis
Chapter 13 South America Hemophilia Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Hemophilia Treatment Business
Chapter 15 Hemophilia Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2012
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027